



EVI Rendez-Vous
9th December 2015
Auditorium Jacob - Institut Pasteur
28, rue Dr Roux - 75015 Paris

08:15	Registration - Welcome coffee	EVI crew
08:45	Welcome	Claude Leclerc
08:50	Organisation remarks	Odile Leroy
09:00	Keynote speaker Helminths and poverty related diseases vaccines: Scientific hypothesis generated by IDEA	Matthieu Perreau
09:20	EVI Portfolio	Odile Leroy

Preclinical Activities - Nathalie Garçon and Joachim Hombach

09:40	<i>Staphylococcus aureus</i> - antigen discovery	David Wyllie (BELLEROPHON)
10:00	Diversity covering approach for universal flu vaccines: updates from the EDUFLUVAC project	Ed Remarque (EDUFLUVAC)
10:20	<i>Coffee Break</i>	
10:40	PAMVAC placental malaria vaccine candidate; production and adjuvants' selection	Morten Nielsen (PAMCPH/PlacMalVac)
11:00	PRIMVAC pre-clinical activities and GMP production	Benoit Gamain and Sophie Hallez (PRIMALVAC)
11:20	Placental malaria animal model	Patrick Duffy (PlacID)

Harmonisation Activities - Aissatou Toure

11:40	Standardisation and development of assays for assessment of influenza vaccine correlate of protection	Emanuele Montomoli (FLUCOP)
11:55	Harmonisation of immunoassays for universal flu vaccines	Othmar Engelhardt (EDUFLUVAC)
12:10	Development of a paratyphoid human infection model to accelerate vaccine development	Andrew Pollard (PIM)
12:40	<i>Group picture</i>	
12:50	<i>Lunch break</i>	

Clinical Activities - Salim Abdulla and Sam McConkey

14:00	PfRH5 blood stage malaria vaccine candidate; antigen optimisation, production and phase I/II clinical trial	Simon Draper (InnoMalVac and MultiMalVax)
14:20	Final results of a phase I/IIb clinical trial with ChAd63/MVA ME-TRAP in Burkinabe infants	Jean-Baptiste Yaro (MVVC)
14:40	Results of a phase Ib clinical trial in infants (the MRC/UCAD experience)	Victorine Mensah (MVVC 2)
15:00	Development of a multi-component multistage malaria vaccine	Adrian Hill (MultiMalVax)

Today's Catalyst For Tomorrow's Vaccines

15:20	<i>Plasmodium falciparum</i> blood-stage vaccine BK-SE36	Toshihiro Horii (SEmalvac)
15:40	AMA1-DiCo clinical trial phase Ia/Ib: Safety and preliminary immunogenicity results	Christine Durier, Odile Launay and Esperance Ouedraogo (AMA1-DiCo)
16:10	<i>Coffee Break</i>	
16:30	Safety and immunogenicity of novel candidate blood-stage malaria vaccine P27A with Alhydrogel® or GLA-SE as adjuvant in healthy malaria non-exposed European and malaria exposed African adults aged 18-45 years	François Spertini, Regine Audran, Seif Shekalaghe, and Claudia Daubenberger (P27A)
17:00	Helminths and TB vaccine candidate	Anne Wajja (IDEA)

Roadmap – Clemens Kocken

17:20	Roadmap for vaccine R&D	Michael Watson (IPROVE)
17:40	EVI strategic plan 2016-2020	Odile Leroy
18:00	<i>Closing remarks</i>	<i>Clemens Kocken</i>